Multiple Ascending Oral Dose 14-Day Trial of LHF-535 in Healthy Participants

Inclusion Criteria: * Male or female 18 to 50 years of age, inclusive, at the time of screening * Able to understand the requirements of the study, to provide written informed consent (as evidenced by signature on an informed consent document that is approved by a Human Research Ethics Committee \[HREC\]), and agreeable to abide by the study restrictions * Body mass index (BMI) of 18.0 to 35.0 kg/m\^2, inclusive, at the time of screening * Weight between 50 kg and 110 kg, inclusive, at the time of screening and check-in (Day -1) * Good general health (e.g., no chronic health conditions such as hypertension, diabetes, chronic obstructive pulmonary disease, or cardiovascular disease) as determined by the Investigator; participants with mild allergies or benign conditions such as Gilbert's disease may be enrolled at the discretion of the Investigator * Female participants of child-bearing potential, with a fertile male sexual partner, must use a highly effective method of contraception (oral contraceptive, intrauterine device, or hormonal patch, injectable, or implantable device) in conjunction with a male condom during the screening period and for the entire duration of study participation including the 28-day follow-up; true abstinence from sexual intercourse with a partner of the opposite sex, in accordance with the preferred and usual lifestyle of the participant, is acceptable; periodic abstinence or avoiding sexual intercourse on days while the participant is fertile (cal…